Fortunately, new pharmaceutical manufacturing technologies are being developed to produce a series of PD-1 inhibitors (PD-1/CTLA-4, PD-1/CD47, PD-1/LAG-3, etc.), which could potentially be used in the future to treat advanced ESCC. This evidence concerns the gene CTLA4 and esophageal squamous cell carcinoma.